

Aziz Zaanan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1615713/publications.pdf>

Version: 2024-02-01

62
papers

2,108
citations

257450

24
h-index

243625

44
g-index

64
all docs

64
docs citations

64
times ranked

3607
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.9	3
2	Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 114-118.	2.8	4
3	Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). <i>Gastric Cancer</i> , 2022, 25, 586-597.	5.3	8
4	Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives. <i>Cancers</i> , 2022, 14, 1137.	3.7	5
5	Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4427.	4.1	6
6	Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. <i>Liver Cancer</i> , 2022, 11, 460-473.	7.7	13
7	Localized Small Bowel Adenocarcinoma Management: Evidence Summary. <i>Cancers</i> , 2022, 14, 2892.	3.7	9
8	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	6.3	5
9	Panel gene profiling of small bowel adenocarcinoma: Results from the <scp>NADEGE</scp> prospective cohort. <i>International Journal of Cancer</i> , 2021, 148, 1731-1742.	5.1	21
10	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	2.8	18
11	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101681.	1.5	4
12	Prognostic factors of colorectal cancer patients with brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 158, 67-73.	0.6	9
13	Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E mutated metastatic colon cancer. <i>European Journal of Cancer</i> , 2021, 152, 1-3.	2.8	2
14	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	0
15	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021, 13, 4743.	3.7	8
16	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	3.7	6
17	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. <i>Statistical Methods in Medical Research</i> , 2020, 29, 541-567.	1.5	8
18	Plasma clearance of <i>RAS</i> mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1185-1189.	5.1	26

#	ARTICLE	IF	CITATIONS
19	Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. <i>International Journal of Cancer</i> , 2020, 147, 967-977.	5.1	57
20	Effectiveness of a dedicated small bowel neoplasia screening program by capsule endoscopy in Lynch syndrome: 5 years results from a tertiary care center. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093431.	3.2	2
21	Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study. <i>EBioMedicine</i> , 2020, 60, 102979.	6.1	2
22	A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. <i>British Journal of Cancer</i> , 2020, 123, 811-818.	6.4	39
23	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. <i>Drugs</i> , 2020, 80, 401-415.	10.9	42
24	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	5.1	56
25	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102028.	7.7	9
26	Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries. <i>Pleura and Peritoneum</i> , 2020, 5, 20190035.	1.2	1
27	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	10.9	48
28	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , 2019, 121, 434-442.	6.4	54
29	Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study. <i>EBioMedicine</i> , 2019, 41, 276-285.	6.1	19
30	How to better select patients with advanced gastric cancer for immunotherapy. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 6-6.	3.0	8
31	Characteristics of <i>BRAF</i> V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	3.7	20
32	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 331-335.	1.0	24
33	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , 2018, 50, 408-410.	0.9	14
34	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 396-402.	1.5	14
35	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. <i>Targeted Oncology</i> , 2018, 13, 107-112.	3.6	8
36	Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocolangiocarcinoma: an AGEO French multicentre retrospective study. <i>British Journal of Cancer</i> , 2018, 118, 325-330.	6.4	37

#	ARTICLE	IF	CITATIONS
37	Colorectal Cancer: Why Does Side Matter?. <i>Drugs</i> , 2018, 78, 789-798.	10.9	41
38	Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2018, 50, 768-779.	0.9	73
39	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	6.4	22
40	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). <i>Clinical Cancer Research</i> , 2017, 23, 5416-5425.	7.0	189
41	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. <i>Oncotarget</i> , 2017, 8, 101383-101393.	1.8	31
42	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 1498-1502.	0.9	8
43	Small Bowel Adenocarcinoma. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 447-457.	2.2	48
44	A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. <i>Clinical Chemistry</i> , 2016, 62, 1129-1139.	3.2	111
45	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. <i>Digestive and Liver Disease</i> , 2016, 48, 441-445.	0.9	17
46	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. <i>JAMA Oncology</i> , 2016, 2, 643.	7.1	125
47	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv438.	6.3	127
48	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 154-160.	1.5	33
49	Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. <i>Quality of Life Research</i> , 2016, 25, 1713-1723.	3.1	28
50	Hypermethylated circulating DNA detection using picoliter droplet-based PCR in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 622-622.	1.6	0
51	Secondâ€line chemotherapy for advanced biliary tract cancer after failure of the gemcitabineâ€platinum combination: A large multicenter study by the Association des Gastroâ€ntâ€rologues Oncologues. <i>Cancer</i> , 2015, 121, 3290-3297.	4.1	95
52	Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial. <i>PLoS ONE</i> , 2015, 10, e0125350.	2.5	7
53	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4027-4027.	1.6	1
54	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. <i>Journal of Cancer</i> , 2014, 5, 425-432.	2.5	30

#	ARTICLE	IF	CITATIONS
55	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1740-1746.	2.8	79
56	Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 97-104.	0.9	245
57	Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3508-3508.	1.6	9
58	Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4093-4093.	1.6	2
59	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma: Preliminary results of an AGEO multicentric retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15018-e15018.	1.6	0
60	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3549-3549.	1.6	0
61	Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy. <i>Cancer</i> , 2011, 117, 1422-1428.	4.1	71
62	Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 7470-7478.	7.0	76